Qurient said Tuesday that it has completed patient enrollment for phase 2b clinical trials of Q301, an atopic dermatitis treatment, in the United States.

Unlike the previous phase 2a clinical trials, the clinical trial has lowered the participants’ age to 12 years and older. The company plans to verify the drug's safety and efficacy by administering a clinical reagent developed in commercial formulations for eight weeks.

Qurient kicked off the clinical trial by administering the treatment to the first enrolled patient in November 2018 at more than 20 hospitals throughout the U.S.

Considering the schedule of dosing and analyzing remaining patients after the completion of the recruitment, the company will be able to confirm the results of the trial by the end of this year.

The completion of patient enrollment comes after the company presented the phase 2a clinical trial results for Q301 at the annual American Academy of Dermatology in March of this year.

Phase 2a clinical trials, also conducted in the U.S., showed that 30 percent of patients receiving Q301 had their symptoms improve, compared to the 4 percent from the control group. The treatment also had similar side effects compared with the control group.

"We are very pleased that the U.S. clinical trials are proceeding as planned," Qurient CEO Nam Ki-yean said. "We will proceed with the remaining schedule so that we can make achieve good results for Q301, which is the company's leading development project."